The prognosis of infant ALL, characterized by a high incidence of the immature CD10 negative B-lineage ALL (proB ALL) is poor. This study aimed to determine the resistance profile of infant ALL cells. In vitro drug resistance was determined by the MTT assay of 395 children with ALL at initial diagnosis: there were 21 infants Ͻ Ͻ Ͻ1.5 years of which nine Ͻ Ͻ Ͻ1 year, 284 children aged 1.5-10 years (intermediate age group) and 90 children Ͼ Ͼ Ͼ10 years. Immunophenotyping resulted in 310 cALL/preB ALL, 69 T-ALL, 15 proB ALL and one unknown cases. The following drugs were tested: daunorubicin, doxorubicin, mitoxantrone, idarubicin (Ida), prednisolone (Pred), dexamethasone (DXM), vincristine (VCR), Asparaginase (Asp), 6-MP, 6-TG, AraC, VM26 and 4-HOO-ifosfamide (Ifos). Infants Ͻ Ͻ Ͻ1.5 years were significantly more resistant to Pred (Ͼ Ͼ Ͼ500-fold), Asp (11-fold) and VM26 (2.7-fold) but significantly more sensitive to Ara-C (2.3-fold) compared to the intermediate age group. When analyzing infants Ͻ Ͻ Ͻ1 year of age similar results were found. ProB ALL cells (seven infants Ͻ Ͻ Ͻ1.5 years; eight children Ͼ Ͼ Ͼ1.5 years) were significantly more resistant to glucocorticoids, Asp, thiopurines, anthracyclines and Ifos compared to cALL/preB ALL but more sensitive to Ara-C. Cells from children Ͼ Ͼ Ͼ10 years were significantly more resistant to Pred, DXM, Asp, Ida and 6-MP. T-ALL cells showed a strong resistance to Pred, Asp and VCR and a mild but significant resistance to all other drugs except thiopurines and VM26. We conclude that the poor prognosis of infant ALL is associated with a resistance to glucocorticoids and Asp. However, ALL cells from infants show a relatively high sensitivity to Ara-C which suggests that infants with ALL might benefit from treatment schedules that incorporate more Ara-C than the current treatment protocols.
Introduction
The prognosis of children with acute lymphoblastic leukemia (ALL) has improved dramatically over the last decades. About 75% of all children will be long-term survivors. 1 However, for some subgroups the prognosis is still poor. Very young children, ie infants with ALL defined at below 1 or 1.5 years of age, form one of these subgroups. In small series using different treatment protocols, the event-free survival (EFS) of infant ALL is about 35%. 2 Retrospective analyses of two larger series of, respectively, 115 3 and 88 infants 4 show a 4-year EFS not higher than 25%.
Infant ALL is characterized by a high frequency of a high white blood cell count (WBC), hepatosplenomegaly and central nervous system involvement. 3, 4 Most infants have a very immature precursor B-lineage ALL, also called pre-preB ALL or proB ALL, that lacks CD10 expression and often coexpresses myeloid-associated antigens. The frequency of MLL gene (11q23) rearrangements is very high in infant leukemia. These characteristics are highly interrelated and are inversely related to the age of the infant. 4, [6] [7] [8] [9] [10] [11] More than 90% of infants with ALL enter complete remission but many suffer from an early relapse. In other words, the factors age, MLL rearrangement, proB ALL or myeloid coexpression might cause or reflect some kind of drug resistance. Earlier studies from our laboratory suggested that infant-and proB ALL cells were relatively resistant to some of the drugs used in treatment of ALL. 12, 13 In the present study, we have reviewed the in vitro drug resistance profiles of 395 children with ALL analyzed in our laboratory. The aim was to determine the resistance profile of infant ALL cells. In addition the resistance profiles of other high risk groups as defined by age and phenotype, ie T-ALL and children aged Ͼ10 years are given for comparison.
Materials and methods

Cells
Freshly obtained or cryopreserved cells derived from bone marrow or peripheral blood of 395 children with newly diagnosed, untreated ALL were used, which were obtained from the COALL study group, DCLSG, VU Hospital and Copenhagen. Part of the data have been published before. 12, 13 Leukemic cells were isolated by centrifugation (480 g, 15 min) with Lymphoprep (1.077 g/ml; Nycomed Pharma, Oslo, Norway). After isolation, the cells were washed twice in RPMI 1640 (Dutch modification; Gibco BRL, Breda, The Netherlands) containing 1% fetal calf serum (FCS; Gibco BRL). All samples contained Ͼ80% leukemic cells.
Immunophenotyping was performed at reference laboratories of the participating groups. 
In vitro drug resistance assay
In vitro drug resistance was assessed with the MTT assay as described.
14 Briefly, 96-well microculture plates contained 100 l cell suspension with six duplicate concentrations of each drug. The used concentrations are based upon earlier studies as to obtain LC 50 values in both highly sensitive and resistant cases. The following drugs and range of concentrations were used: daunorubicin (DNR; 0.002-2 g/ml), mitoxantrone (Mit; 0.001-1.0 g/ml), doxorubicin (Dox; 0.008-8.0 g/ml), idarubicin (Ida; 0.002-2 g/ml), prednisolone (Pred; 0.1-250 g/ml), dexamethasone DXM; (0.002-6 g/ml), vincristine (VCR; 0.05-50 g/ml), Asparaginase (Asp; 0.003-10 IU/ml), 6-mercaptopurine (6-MP; 15.6-500 g/ml), 6-thioguanine (6-TG; 1.6-50 g/ml), cytosine arabinoside (Ara-C; 0.002-2.5 g/ml), teniposide (VM26, 0.003-8 g/ml), and 4-HOO-ifosfamide (Ifos; 0.10-100 g/ml). Untreated control leukemic cells were set up in eight-fold. After 4-days incubation in humidified air containing 5% CO 2 at 37°C, 10 l MTT solution (5 mg/ml) was added to each well after which the plate was incubated for another 6 h. The tetrazolium salt MTT is reduced into a coloured formazan product by living but not by dead cells. The formazan crystals were dissolved with 100 l of acidified isopropanol. The optical density (OD) of the wells was measured with a microplate reader (Bio-Kinetics Reader; Bio-Tek Instruments, Winooski, VT, USA) at 562 nm. The OD is linearly related to the viable cell number. 15 Leukemic cell survival (LCS) was calculated by the following equation: LCS = (mean OD treated wells/mean OD control wells) × 100%. Drug resistance was expressed by the LC 50 , ie the drug concentration lethal to 50% of the cells. Previous studies showed that cryopreservation does not alter drug resistance 16 and that bone marrow and peripheral blood cells do not differ in drug resistance. 17 
Statistics
The Mann-Whitney U test was used for two-tailed testing at a P-value of 0.05 which should be interpreted with caution because of the multiple comparisons that are made.
Results
The age distribution was as follows: 21 infants Ͻ1.5 years of whom nine were below 1 year old; 284 children between 1.5 and 10 years; 90 were 10 to 20 years old. Results of immunophenotyping were available in 394 patients: 15 proB ALL, 310 cALL/preB ALL and 69 T-lineage ALL. The distribution of the different immunophenotypes within the different age categories is shown in Table 1. ALL cells from infants aged Ͻ1.5 years were significantly more resistant to Pred (Ͼ500-fold), Asp (11-fold) and VM26 (2.7-fold) compared to ALL cells from children between 1.5 and 10 years old. Remarkably, infant ALL cells were significantly more sensitive to Ara-C than ALL cells from children between 1.5 and 10 years old (median 2.3-fold) ( Table 2) . For the anthracyclines, VCR, thiopurines, Ifos and mitoxantrone no significant differences were detected (Table 2) .
When infants Ͻ1 year of age were compared to children aged 1-10 years, comparable results were found: cells from the infants Ͻ1 year were significantly more resistant to Pred (Ͼ500-fold), DXM (Ͼ86-fold) and Asp (9.6-fold) but more sensitive to Ara-C (2.4-fold) compared to ALL cells from children between 1 and 10 years old.
The immunophenotype proB ALL was found in seven infants Ͻ1.5 years of age and in eight children above this age. The group of 15 proB ALL cases was significantly more resistant to Pred (332-fold), DXM (39-fold), DNR (2.8-fold), Dox (1.6-fold), Asp (8.2-fold), the thiopurines 6-MP (4.2-fold) and 6-TG (1.9-fold) and Ifosfamide (1.6-fold) than the cALL/preB ALL group (Table 3) . However, proB ALL cells were more sensitive to Ara-C (2.3-fold) compared to cALL/preB ALL cells.
T-ALL cells were significantly more resistant than cALL-preB ALL to almost all drugs tested, except to thiopurines and VM-26. The degree of resistance of T-ALL cells was the highest for Pred, Asp and VCR. ALL cells from children aged Ͼ10 years were significantly more resistant to Pred, DXM, Asp, 6-MP and Ida compared to ALL cells from children between 1.5 and 10 years old. The same results were found for these older children vs the intermediate age group when only cALL/preB ALL cases were analyzed.
Discussion
The present report shows that infant ALL cells are in vitro highly resistant to glucocorticoids and Asp. This is in agree-
Figure 2
Phenotype vs resistance in ALL with Ara-C. The numbers represent numbers of ALL cases.
ment with the poor outcome of infants with ALL and with the fact that in vitro resistance to these drugs was associated with a poor outcome in ALL. [18] [19] [20] A striking finding was that infant ALL cells were highly sensitive to Ara-C which is interesting in the light of the fact that infants often have a very immature type of B-lineage ALL with myeloid characteristics, and Ara-C is known as a potent anti-myeloid leukemia drug. We also found that the proB ALL cases were more resistant to glucocorticoids and Asp but more sensitive to Ara-C compared to the cALL/preB ALL cases. It has to be taken into account that the number of infants and proB ALL cases studied is low. Therefore, it is not possible to analyze which of the characteristics, ie age or phenotype was responsible for this specific resistance/sensitivity profile. Also, the cytogenetic abnormalities were not known in the majority of cases. In a currently ongoing project we study the relationship between MLL rearrangement and drug resistance, also including methotrexate and 2-chlorodeoxyadenosine. Of interest is a recent German study (W-D Ludwig, personal communication) showing a markedly improved prognosis for adults with proB ALL both with and without MLL rearrangement since the introduction of high-dose Ara-C. A small study in infant ALL also reported an increase in survival with the use of an intensification block mainly consisting of high-dose Ara-C and high-dose methotrexate. 21 The high sensitivity to Ara-C in vitro, the preliminary clinical data mentioned above and the co-expression of myeloid antigens suggest that infants with ALL might benefit from a so-called hybrid 'lymphatic/myeloid' treatment schedule that includes more Ara-C than current ALL protocols. In addition, the ALL cells from infants were relatively more resistant to Pred than to DXM which might perhaps suggest that dexamethasone is even more useful in infants than in older age groups.
T-ALL cells showed a general drug resistance when compared to precursor B-lineage ALL cells. This might reflect a defect in a final common pathway for different drugs, presumably far downstream in the drug-induced apoptotic cascade. For most drugs, the degree of resistance of T-ALL cells was only moderate but for Pred, Asp and VCR the degree of resistance was relatively high. This resistance might contribute to the poorer prognosis of T-ALL compared to cALL/preB ALL. Leukemic cells from older children with ALL, ie children aged Ͼ10 years, were more resistant to glucocorticoids, Asp and 6-MP. This might partly explain the poorer outcome of older children with ALL. It could be part of a trend that with the increasing age of the patient, ALL cells become more resistant, especially to glucocorticoids. Maung et al 22 described that cells from adults with ALL are more resistant to Pred than cells from children with ALL.
The results described in the present study should be seen in the perspective that in different studies, in vitro resistance to glucocorticoids and Asp appeared to be a strong and independent prognostic factor in childhood ALL [18] [19] [20] and that cells from children with ALL at relapse were resistant to many 1347 Table 3 Immunophenotype vs drug resistance Values represent median LC 50 values with the 25th and 75th percentiles given between brackets. P values represent the comparisons of the proB ALL or T-ALL group vs the cALL/preB ALL. n = 4-15 for proB ALL, n = 108-282 for cALL/preB ALL and n = 22-63 for T-ALL.
classes of drugs but especially to glucocorticoids and Asp. 23 All high-risk categories of patients defined by age and immunophenotype described in this paper (infants, older children, proB ALL, T-ALL) showed marked in vitro resistance to at least these two classes of drugs. With the exception of defects in the glucocorticoid receptor and a high activity of asparagine synthetase in ALL cells, little is known about the resistance mechanisms to these drugs that are clinically relevant for childhood ALL. 24 Anti-asparaginase antibodies can contribute to Asp resistance and might differ with age but the cells tested in this study were obtained at initial diagnosis before therapy was given. Why infants' ALL cells and proB ALL cells are more sensitive to Ara-C is also unknown. The limited data available on Ara-C sensitivity in childhood ALL show that AraCTP formation is correlated to the immunophenotype: T-ALL cells showed lower amounts of AraCTP than cALL cells, 24 which is in agreement with our findings that T-ALL cells are less sensitive to this drug than cALL/preB-ALL cells. However, there are no published data concerning AraCTP formation in infants' or proB ALL cells.
We conclude that the poor prognosis of infants with ALL is related to resistance to glucocorticoids and Asp. However, ALL cells from infants show a relatively high sensitivity to Ara-C which suggests that infants with ALL might benefit from treatment schedules that incorporate more Ara-C than the current treatment protocols.
